GlassScriptPhysician profile
Ashley T Lowe
NPI 1194768184
$1,708.12
in general payments reported to CMS, 2019-2025
29 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $560 · 2022: $465 · 2023: $321 · 2024: $114 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.22 | 2021-2025 | |
| Novo Nordisk INC | $208.22 | 2021-2025 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $112.68 | 2021-2025 | Gvoke Hypopen |
| Janssen Biotech, INC. | $101.66 | 2023 | Erleada |
| Merck Sharp & Dohme LLC | $88.58 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $88.31 | 2021-2023 | Farxiga |
| Glaxosmithkline, LLC. | $78.51 | 2021-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $68.35 | 2021-2024 | Jardiance, Mounjaro, Trulicity |
| Sanofi-Aventis U.S. LLC | $67.08 | 2021 | |
| Pfizer INC. | $58.54 | 2021-2024 | |
| Abbott Laboratories | $52.66 | 2021-2023 | Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $51.46 | 2021-2025 | Nexletol |
| Urovant Sciences INC | $48.60 | 2022 | |
| Exact Sciences Corporation | $37.65 | 2024-2025 | Cologuard Collection Kit |
| Acadia Pharmaceuticals INC | $32.89 | 2022-2025 | Nuplazid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $27.95 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $25.98 | 2021 | |
| Scilex Pharmaceuticals INC. | $25.04 | 2025 | |
| Cvrx, INC. | $24.25 | 2024-2025 | Barostim Neo System |
| Axsome Therapeutics, INC. | $20.46 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $18.73 | 2023 | Rexulti |
| Boston Scientific Corporation | $18.27 | 2025 | Watchman Flx |
| Collegium Pharmaceutical, INC. | $17.98 | 2021 | |
| Virtus Pharmaceuticals LLC | $14.71 | 2021 | |
| Mylan Specialty L.P. | $14.60 | 2021 | |
| Tactile Systems Technology INC | $14.15 | 2024 | Flexitouch Plus, Entre Plus |
| Forte Bio-Pharma LLC | $13.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.